重组人血管内皮抑制素腹腔灌注联合静脉化疗治疗晚期卵巢癌

Treatment of Intraperitoneal Perfusion of Recombinant Human Endostatin Combined with Intravenous Chemotherapy on Advanced Ovarian Cancer

目的:研究静脉化疗与重组人血管内皮抑制素(恩度)对晚期卵巢癌进行联合治疗的效果。方法:选取2015年1月-2017年4月在本院接受治疗的92例晚期卵巢癌患者,将其分为两组,每组46例。对照组行静脉化疗,观察组应用恩度腹腔灌注联合静脉化疗,对比两组治疗效果、毒副反应发生情况及治疗后1、2年复发率和生存率。结果:治疗后,对照组总有效率低于观察组(χ^2=3.9030,P=0.0481);对比1、2年复发率与生存率,观察组复发率更低,生存率更高(P<0.05);两组不良反应比较,差异无统计学意义(P>0.05)。结论:静脉化疗联合恩度腹腔灌注晚期卵巢癌进行联合治疗,可有效增强治疗效果,不良反应可耐受。

Objective:To study the effect of chemotherapy combined with Recombinant Human Endostatin(Endu)on advanced ovarian cancer.Method:A total of 92 patients with advanced ovarian cancer who were treated in our hospital from January 2015 to April 2017 were divided into two groups,46 in each group.The control group was given intravenous chemotherapy,the observation group was given intraperitoneal perfusion of Endu combined with intravenous chemotherapy,and the therapeutic effect,the occurrence of side effects,the recurrence rate and survival rate of 1 and 2 years after treatment were compared between the two groups.Result:After treatment,the total effective rate of the control group was lower than that of the observation group(X^2=3.9030,P=0.0481).The recurrence rate and survival rate in 1 year or 2 years of the observation group were lower or higher than those of the observation group(P<0.05).There was no significant difference in adverse reactions between the two groups(P>0.05).Conclusion:Intravenous chemotherapy combined with Endu intraperitoneal perfusion for advanced ovarian cancer can effectively enhance the therapeutic effect,and the adverse reactions can be tolerated.